Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
StemRIM Inc. ( (JP:4599) ) just unveiled an announcement.
StemRIM Inc. announced a protocol amendment for its global Phase 2b clinical trial of Redasemtide, a treatment for acute ischemic stroke, which is being conducted in collaboration with Shionogi & Co., Ltd. The amendment includes adding a new cohort of patients who have undergone endovascular recanalization therapy and relaxing eligibility criteria, allowing broader patient participation without significantly extending the trial period. This adjustment is crucial as the market for ischemic stroke treatments is expected to reach $10.56 billion by 2027, and the changes aim to adapt to the evolving treatment landscape.
More about StemRIM Inc.
StemRIM Inc. is a biotech venture originating from Osaka University, focused on developing ‘Regeneration-Inducing Medicine’ that aims to achieve regenerative therapy effects through drug administration without using living cells or tissues. The company is working on products that mobilize mesenchymal stem cells to promote tissue repair and regeneration.
YTD Price Performance: 4.14%
Average Trading Volume: 167,982
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen20.35B
For an in-depth examination of 4599 stock, go to TipRanks’ Stock Analysis page.